{"id":"low-dose-quillivant-xr","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Decreased appetite"},{"rate":"15-25","effect":"Insomnia or sleep disturbance"},{"rate":"10-20","effect":"Headache"},{"rate":"10-15","effect":"Abdominal pain"},{"rate":"5-15","effect":"Nervousness or anxiety"},{"rate":"5-10","effect":"Tachycardia"},{"rate":"5-10","effect":"Elevated blood pressure"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methylphenidate is a central nervous system stimulant that works by blocking the reuptake of dopamine and norepinephrine at the presynaptic neuron, thereby increasing their concentration in the synaptic cleft. The extended-release formulation provides sustained drug delivery over 12 hours, allowing for once-daily dosing. This mechanism enhances executive function, attention span, and impulse control in patients with ADHD.","oneSentence":"Quillivant XR is an extended-release formulation of methylphenidate that increases dopamine and norepinephrine activity in the central nervous system to improve attention and reduce hyperactivity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:53:28.376Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents"}]},"trialDetails":[{"nctId":"NCT02255565","phase":"PHASE4","title":"Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study","status":"COMPLETED","sponsor":"Seattle Children's Hospital","startDate":"2014-09","conditions":"ADHD, Autism","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Methylphenidate HCl"],"phase":"marketed","status":"active","brandName":"Low Dose Quillivant XR","genericName":"Low Dose Quillivant XR","companyName":"Seattle Children's Hospital","companyId":"seattle-children-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Quillivant XR is an extended-release formulation of methylphenidate that increases dopamine and norepinephrine activity in the central nervous system to improve attention and reduce hyperactivity. Used for Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}